TEVA NYSE Pharmaceuticals Financials FY2016βFY2025
Teva makes and sells medicines in two groups: generics, which are lower-cost copies of drugs whose patents have expired, along with biosimilars and over-the-counter products, and its own branded medicines. It is based in Israel, has about 34,000 employees across 57 markets, and has a large presence in the United States and Europe. Its generics are sold mainly to retail drug chains, mail-order distributors and wholesalers.
Hi! I read Teva Pharmaceuticalsβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+4.3%
Only a little. Sales grew 4.3% last year.
Does it make a profit?
8.2%
A little. It keeps 8.2% of every sale as profit.
Does profit turn into cash?
6.7%
Partly. 6.7% of sales ends up as free cash.
Is debt under control?
4.2x
Heavy. Repaying its debt would take 4.2 years of operating profit.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
65.7x
One share costs 65.7 times its yearly profit per share. Typical for its sector: 27.9x.
Rules of thumb on reported numbers. A starting point, not a recommendation.
About these figures. Teva's debt is its long-term senior notes and loans plus its short-term debt, as on its balance sheet; the default found only part of it. Teva's fiscal 2025 10-K tags one product's fourth-quarter sales as revenue, so its revenue is taken from its total sales line.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Teva Pharmaceuticals did it, and the next one. Share prices often move a lot on those days.
Next results
November 3, 2026
Tuesday Β· in 8 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 29, 2026 | Q2 '26 | Before the market opens | 8-K β |
| Apr 29, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 11, 2026 | Q4 '25 | Time not announced | 8-K β |
| Nov 5, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Jul 30, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 7, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Jan 29, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 6, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Teva Pharmaceuticals had $17.3B of revenue in fiscal 2025, up 4.3% on the year before. Over five years, revenue changed +0.7% a year on average. Its operating margin was 12.5%, up 14.3Β pts: of every 100 in sales, about 13 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Teva Pharmaceuticals made $1.4B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 37.3% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $1.1B in fiscal 2025, 6.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Teva Pharmaceuticals returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 2.8%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $21.7M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$21.7M
11 insiders
Of sales under plans
29%
$6.4M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Brian SavageInterim Chief Legal Officer | Sold | 7,342 | $38.85 | $0.3M | Form 4 |
| Sep 18, 2026 | Roberto MignoneDirector | Sold | 367,600 | $39.06 | $14.4M | Form 4 |
| Aug 21, 2026 | Amir WeissChief Accounting Officer | Sold | 9,445 | $37.62 | $0.4M | Form 4 |
| Aug 21, 2026 | Ronit Satchi-FainaroDirector | Sold | 415 | $37.25 | $0.0M | Form 4 |
| Aug 17, 2026 | Evan LippmanEVP, Business Development | Sold plan | 18,600 | $36.57 | $0.7M | Form 4 |
| Aug 5, 2026 | Tal Zvi ZaksDirector | Sold | 17 | $34.87 | $0.0M | Form 4 |
| Aug 3, 2026 | Eric A Hughes"See ""Remarks""" | Sold plan | 25,578 | $34.88 | $0.9M | Form 4 |
| Aug 3, 2026 | Placid Jover"See ""Remarks""" | Sold plan | 12,827 | $34.88 | $0.4M | Form 4 |
| Jun 18, 2026 | Matthew ShieldsEVP, Global Operations | Sold | 9,989 | $32.19 | $0.3M | Form 4 |
| Jun 11, 2026 | Eliyahu Sharon KalifEVP, Chief Financial Officer | Sold plan | 106,563 | $34.10 | $3.6M | Form 4 |
| Jun 5, 2026 | Richard D FrancisPresident and CEO | Sold plan | 6,153 | $34.35 | $0.2M | Form 4 |
| Jun 3, 2026 | Matthew ShieldsEVP, Global Operations | Sold plan | 16,195 | $32.87 | $0.5M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Teva Pharmaceuticals owes $13.3B more than it holds in cash, about 4.2 years of operating profit.
Cash, debt and the ratios that show how comfortably Teva Pharmaceuticals can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.2B | $2.8B | $3.2B | $3.3B | $3.6B |
| Debt incl. finance leases | $23.1B | $21.2B | $19.9B | $17.8B | $16.8B |
| Net debt / EBITDA | 6.9x | β | 10.5x | 19.2x | 4.2x |
| Debt / equity | 2.2x | 2.7x | 2.7x | 3.3x | 2.1x |
| Interest coverage | 1.9x | β2.4x | 0.4x | β0.3x | 2.4x |
| Current ratio | 1.1x | 1.1x | 1.0x | 1.0x | 1.0x |
| Quick ratio | 0.8x | 0.7x | 0.7x | 0.8x | 0.8x |
| Total assets | $47.7B | $44.0B | $43.5B | $39.3B | $40.7B |
| Total liabilities | $36.4B | $35.4B | $35.4B | $33.6B | $32.8B |
| Shareholders' equity | $10.3B | $7.8B | $7.5B | $5.4B | $7.9B |
| Net debt (β = net cash) | $20.9B | $18.4B | $16.6B | $14.5B | $13.3B |
KIRA Β· Its return on capital was 10.5%: every 100 invested in the business earned about 11 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Teva Pharmaceuticals passes 8 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 6 / 9 | 5 / 9 | 8 / 9 |
| Accruals ratio | β4.4% | β7.0% | β0.6% |
| Altman Z'' | β0.67 | β1.18 | β0.41 |
What does the share cost, and how does it compare?
KIRA Β· At $39.41 a share, the company is worth $45.9B: 65.7 times its earnings of the last four quarters.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
β
Adds net cash of β$13.3B and divides by 1,163.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
β
Reference multiples: today 65.7x Β· peers 13.4x Β· sector 27.9x.
KIRA Β· Teva Pharmaceuticals grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 2 of 2.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Teva Pharmaceuticals TEVA | $45.9B | 4.3% | 12.5% | 6.7% | 10.5% | 65.7x | 8 | |
| Viatris VTRS | $20.9B | β3.0% | β18.6% | 13.6% | β7.1% | β | 4 | Compare β |
| Bausch Health Companies BHC | $2.4B | 6.7% | 17.7% | 9.8% | 4.5% | β | 7 | Compare β |
| Zoetis ZTS | $33.8B | 2.3% | β | 24.1% | 29.3% | 13.3x | 8 | Compare β |
| Bristol Myers Squibb BMY | $125.9B | β0.2% | β | 26.7% | 15.2% | 13.5x | 8 | Compare β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $21.9B | $21.9B | $18.3B | $16.9B | $16.7B | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B |
| Gross profit | $11.7B | $10.6B | $8.3B | $7.5B | $7.7B | $7.6B | $7.0B | $7.6B | $8.1B | $8.9B |
| Research and development | $422M | $175M | $114M | $1.0B | $997M | $967M | $98.0M | $953M | $998M | $1.0B |
| Operating income | $2.2B | β$17.5B | β$1.6B | β$443M | β$3.6B | $1.7B | β$2.2B | $433M | β$303M | $2.2B |
| Interest expense | $546M | $875M | $920M | $822M | $901M | $891M | $930M | $1.0B | $1.0B | $916M |
| Pretax income | $824M | β$18.4B | β$2.6B | β$1.3B | β$4.4B | $658M | β$3.2B | β$624M | β$1.3B | $1.2B |
| Income tax | $521M | β$1.9B | β$195M | β$278M | β$168M | $211M | β$643M | β$7.0M | $676M | β$180M |
| Net income | $329M | β$16.3B | β$2.2B | β$999M | β$4.0B | $417M | β$2.4B | β$559M | β$1.6B | $1.4B |
| Diluted EPS | $0.07 | β$16.26 | β$2.35 | β$0.91 | β$3.64 | $0.38 | β$2.20 | β$0.50 | β$1.45 | $1.21 |
| Diluted shares | 0.96B | 1.02B | 1.02B | 1.09B | 1.10B | 1.11B | 1.11B | 1.12B | 1.13B | 1.16B |
| Cash flow | ||||||||||
| Cash from operations | $3.9B | $2.2B | $2.4B | $748M | $1.2B | $798M | $1.6B | $1.4B | $1.2B | $1.6B |
| Capital expenditure | $901M | $874M | $651M | $525M | $578M | $562M | $548M | $526M | $498M | $501M |
| Free cash flow | $3.0B | $1.4B | $1.8B | $223M | $638M | $236M | $1.0B | $842M | $749M | $1.1B |
| Depreciation and amortization | $1.5B | $2.1B | $1.8B | $1.7B | $1.6B | $1.3B | $1.3B | $1.2B | $1.1B | $1.0B |
| Stock-based compensation | $124M | $133M | $155M | $119M | $129M | $119M | $124M | $121M | $123M | $157M |
| Acquisitions | $36.1B | $43.0M | $0.0M | $0.0M | $0.0M | $0.0M | $7.0M | $0.0M | $15.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends paid | $1.3B | $901M | $12.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $1.3B | $901M | $12.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $988M | $963M | $1.8B | $2.0B | $2.2B | $2.2B | $2.8B | $3.2B | $3.3B | $3.6B |
| Total debt | $35.8B | $32.5B | $28.9B | $26.9B | $25.9B | $23.0B | $21.2B | $19.8B | $17.8B | $16.8B |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $29.0M | $21.0M | $25.0M | $22.0M | $32.0M | $23.0M | $43.0M |
| Current assets | $17.2B | $15.4B | $13.8B | $13.5B | $13.0B | $12.6B | $12.1B | $12.5B | $12.6B | $13.9B |
| Current liabilities | $18.5B | $17.9B | $14.3B | $13.7B | $13.2B | $11.0B | $11.5B | $12.2B | $12.8B | $13.5B |
| Inventory | $5.0B | $4.9B | $4.7B | $4.4B | $4.4B | $3.8B | $3.8B | $4.0B | $3.0B | $3.2B |
| Property and equipment, net | $8.1B | $7.7B | $6.9B | $6.4B | $6.3B | $6.0B | $5.7B | $5.8B | $4.6B | $4.1B |
| Total assets | $93.1B | $70.6B | $60.7B | $57.5B | $50.6B | $47.7B | $44.0B | $43.5B | $39.3B | $40.7B |
| Total liabilities | $58.1B | $51.9B | $44.9B | $42.4B | $39.6B | $36.4B | $35.4B | $35.4B | $33.6B | $32.8B |
| Shareholders' equity | $33.3B | $17.4B | $14.7B | $14.0B | $10.0B | $10.3B | $7.8B | $7.5B | $5.4B | $7.9B |
| Margins | ||||||||||
| Gross margin | 53.2% | 48.6% | 45.4% | 44.6% | 46.4% | 47.8% | 46.7% | 48.3% | 48.7% | 51.8% |
| Operating margin | 9.8% | β80.0% | β9.0% | β2.6% | β21.4% | 10.8% | β14.7% | 2.7% | β1.8% | 12.5% |
| EBITDA margin | 16.8% | β70.3% | 1.1% | 7.6% | β12.1% | 19.2% | β6.0% | 10.0% | 4.6% | 18.3% |
| Net margin | 1.5% | β74.4% | β11.8% | β5.9% | β24.0% | 2.6% | β16.4% | β3.5% | β9.9% | 8.2% |
| FCF margin | 13.7% | 6.2% | 9.8% | 1.3% | 3.8% | 1.5% | 7.0% | 5.3% | 4.5% | 6.7% |
| Returns | ||||||||||
| Return on capital | 2.1% | β23.0% | β2.8% | β0.8% | β7.5% | 3.5% | β5.9% | 1.3% | β1.1% | 10.5% |
| Return on capital employed | 3.7% | β27.5% | β3.3% | β1.0% | β8.8% | 4.6% | β6.4% | 1.4% | β1.1% | 8.0% |
| Return on equity | 1.0% | β64.2% | β13.4% | β7.0% | β33.3% | 4.1% | β27.1% | β7.3% | β25.5% | 21.2% |
| Return on assets | 0.5% | β19.9% | β3.3% | β1.7% | β7.4% | 0.9% | β5.3% | β1.3% | β4.0% | 3.5% |
| Growth | ||||||||||
| Revenue growth | 11.5% | β0.2% | β16.4% | β7.6% | β1.4% | β4.7% | β6.0% | 6.2% | 4.4% | 4.3% |
| Net income growth | β79.3% | β5,043.8% | β | β | β | β | β686.6% | β | β | β |
| EPS growth | β96.2% | β23,328.6% | β | β | β | β | β679.0% | β | β | β |
| FCF growth | β37.3% | β54.8% | 32.9% | β87.6% | 186.1% | β63.0% | 341.5% | β19.2% | β11.1% | 53.3% |
| Share count change | 11.2% | 5.7% | 0.5% | 6.9% | 0.4% | 1.1% | 0.3% | 0.8% | 1.1% | 2.8% |
| Financial health | ||||||||||
| Net debt / EBITDA | 9.5x | β | 132.4x | 19.5x | β | 6.9x | β | 10.5x | 19.2x | 4.2x |
| Debt / equity | 1.1x | 1.9x | 2.0x | 1.9x | 2.6x | 2.2x | 2.7x | 2.7x | 3.3x | 2.1x |
| Interest coverage | 4.0x | β20.0x | β1.8x | β0.5x | β4.0x | 1.9x | β2.4x | 0.4x | β0.3x | 2.4x |
| Current ratio | 0.9x | 0.9x | 1.0x | 1.0x | 1.0x | 1.1x | 1.1x | 1.0x | 1.0x | 1.0x |
| Quick ratio | 0.7x | 0.6x | 0.6x | 0.7x | 0.7x | 0.8x | 0.7x | 0.7x | 0.8x | 0.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 4.1% | 4.0% | 3.6% | 3.1% | 3.5% | 3.5% | 3.7% | 3.3% | 3.0% | 2.9% |
| Stock comp / revenue | 0.6% | 0.6% | 0.9% | 0.7% | 0.8% | 0.8% | 0.8% | 0.8% | 0.7% | 0.9% |
| Payouts / FCF | 43.6% | 66.7% | 0.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Quality scores | ||||||||||
| Piotroski F-score | 3.0 | 3.0 | 5.0 | 5.0 | 5.0 | 8.0 | 3.0 | 6.0 | 5.0 | 8.0 |
| Altman Z'' | 1.2 | β1.7 | β0.2 | β0.1 | β0.9 | 0.1 | β1.0 | β0.7 | β1.2 | β0.4 |
| Accruals ratio | β4.8% | β22.6% | β7.0% | β3.0% | β9.6% | β0.8% | β8.8% | β4.4% | β7.0% | β0.6% |
Source: SEC EDGAR XBRL filings (CIK 0000818686). Data updated October 23, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
